中重度化脓性汗腺炎生物治疗强化的潜在预测因素：一项多中心研究。

IF 2.2 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2025-01-07 DOI:10.1111/ajd.14412

Francisco Javier Melgosa Ramos, Ramón García Ruiz, Antonio Martorell

{"title":"中重度化脓性汗腺炎生物治疗强化的潜在预测因素：一项多中心研究。","authors":"Francisco Javier Melgosa Ramos, Ramón García Ruiz, Antonio Martorell","doi":"10.1111/ajd.14412","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Moderate-to-severe hidradenitis suppurativa (HS) is a debilitating disease that often requires biological therapy. Despite the effectiveness of approved doses, some patients experience partial or loss of response over time, leading to the need for dose intensification. This retrospective multicentre study aimed to identify predictors of biological therapy intensification in HS patients. The results showed that prior use of biological treatments and biosimilar adalimumab were significant predictors of intensification, suggesting closer monitoring may be needed for certain patient profiles to optimise treatment outcomes.</p>\n </div>","PeriodicalId":8638,"journal":{"name":"Australasian Journal of Dermatology","volume":"66 2","pages":"e35-e38"},"PeriodicalIF":2.2000,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Potential Predictors of Biological Therapy Intensification in Moderate-To-Severe Hidradenitis Suppurativa: A Multicentre Study\",\"authors\":\"Francisco Javier Melgosa Ramos, Ramón García Ruiz, Antonio Martorell\",\"doi\":\"10.1111/ajd.14412\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <p>Moderate-to-severe hidradenitis suppurativa (HS) is a debilitating disease that often requires biological therapy. Despite the effectiveness of approved doses, some patients experience partial or loss of response over time, leading to the need for dose intensification. This retrospective multicentre study aimed to identify predictors of biological therapy intensification in HS patients. The results showed that prior use of biological treatments and biosimilar adalimumab were significant predictors of intensification, suggesting closer monitoring may be needed for certain patient profiles to optimise treatment outcomes.</p>\\n </div>\",\"PeriodicalId\":8638,\"journal\":{\"name\":\"Australasian Journal of Dermatology\",\"volume\":\"66 2\",\"pages\":\"e35-e38\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-01-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australasian Journal of Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14412\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australasian Journal of Dermatology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ajd.14412","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

中重度化脓性汗腺炎（HS）是一种使人衰弱的疾病，通常需要生物治疗。尽管批准的剂量有效，但随着时间的推移，一些患者出现部分或丧失反应，导致需要增加剂量。本回顾性多中心研究旨在确定HS患者生物治疗强化的预测因素。结果显示，先前使用生物治疗和阿达木单抗生物仿制药是强化的重要预测因素，这表明可能需要对某些患者的情况进行更密切的监测，以优化治疗结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Potential Predictors of Biological Therapy Intensification in Moderate-To-Severe Hidradenitis Suppurativa: A Multicentre Study

Moderate-to-severe hidradenitis suppurativa (HS) is a debilitating disease that often requires biological therapy. Despite the effectiveness of approved doses, some patients experience partial or loss of response over time, leading to the need for dose intensification. This retrospective multicentre study aimed to identify predictors of biological therapy intensification in HS patients. The results showed that prior use of biological treatments and biosimilar adalimumab were significant predictors of intensification, suggesting closer monitoring may be needed for certain patient profiles to optimise treatment outcomes.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.